#USA #San Diego #Class Action #Robbins LLP #Hims & Hers

Recent Developments for Hims & Hers Investors

San Diego, October 19, 2026 – In light of recent actions taken by the Federal Trade Commission (FTC), Robbins LLP, a firm specializing in shareholder rights, is calling attention to a pending class action lawsuit concerning Hims & Hers Health, Inc. (NYSE HIMS). The legal proceedings could deeply impact investors who acquired securities from the company between August 4, 2025, and July 29, 2026. Investors are encouraged to act before the November 2, 2026, lead plaintiff deadline to ensure their voices are heard.

Overview of the Lawsuit

The class action lawsuit aims to represent shareholders who have suffered financial losses during the specified period. According to the allegations, Hims & Hers has been accused of sharing consumers' private health information with third-party advertisers while misleading customers about the security and privacy of its services. Furthermore, the firm has faced scrutiny for its billing methods, which many claim to be deceptive.

Allegations Against Hims & Hers Health, Inc.

The class action complaint highlights several critical points:

1. Privacy Breach: Hims allegedly disclosed sensitive health data to advertising entities, contrary to its promises of confidentiality.
2. Misleading Practices: The company purportedly charged consumers for prescriptions immediately after they submitted an intake form, despite assuring them that they would consult with a medical provider first.
3. Regulatory Spotlight: These practices have drawn regulatory attention, raising the likelihood of financial penalties as well.
4. Material Misrepresentation: Positive statements made by Hims executives regarding the company's stability are claimed to have been misleading or lacking a valid basis.

On July 29, 2026, the FTC officially announced legal actions against Hims, further contributing to the stock's decline by 14.73% or $4.32, closing at $25.00 that same day. This drop reflects the market's reaction to the public announcement, emphasizing the impact of regulatory actions on investor confidence.

Who is Eligible?

Hims & Hers intends to represent individuals and entities that bought stocks during the defined class period. Those impacted are urged to contact Robbins LLP to discuss their potential legal options. It’s noteworthy that the lead plaintiff—an appointed investor who represents all affected parties—has a deadline for notification which is rapidly approaching.

No Cost to Participate

Robbins LLP operates on a contingency fee basis, which means that investors are not obligated to pay upfront costs to join the lawsuit. Financial recovery hinges on the successful resolution of the case, ensuring that clients can pursue their rights without upfront financial barriers.

Why Choose Robbins LLP?

Renowned for their expertise in shareholder rights litigation, Robbins LLP has successfully helped reclaim more than $2 billion in value for shareholders, positioning themselves as a trusted advocate for investors. Brian J. Robbins, the founding partner, emphasizes, "It is essential for companies to uphold their duty to provide accurate and comprehensive information to their investors to maintain fair market practices."

Investors who want to stay informed of developments around the class action lawsuit against Hims should register for notifications through Robbins LLP’s Stock Watch service, which offers timely updates on corporate misconduct and lawsuits.

How to Contact Robbins LLP

For more details about the class action against Hims & Hers Health, Inc., interested investors can reach out to Robbins LLP by completing an inquiry form, sending an email to attorney Aaron Dumas, Jr., or by calling 800-350-6003. Your rights as a shareholder deserve protection, and reaching out before the upcoming deadline is crucial for maximizing your potential recourse.